🇺🇸 FDA
Pipeline program

Dabogratinib (TYRA-300) 60mg

TYR300-203

Phase 2 small_molecule active

Quick answer

Dabogratinib (TYRA-300) 60mg for Low Grade Upper Tract Urothelial Carcinoma is a Phase 2 program (small_molecule) at Tyra Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Tyra Biosciences
Indication
Low Grade Upper Tract Urothelial Carcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials